On March 5, Synageva BioPharma Corp. announced the pricing of its previously announced underwritten public offering of common stock consisting of 2 million shares at $105.75 per share. Willkie represented book-running managers Goldman, Sachs & Co., J.P. Morgan Securities LLC, and Morgan Stanley & Co. LLC, in the offering. In connection with this offering, Synageva granted to the underwriters a 30-day option to purchase 300,000 additional shares of common stock. Massachusetts-based Synageva is a clinical stage biopharmaceutical company developing therapeutic products for life-threatening rare diseases. Willkie previously advised on Synageva’s $113 million and $90 million stock offerings in 2013 and 2012, respectively.

The current deal was handled by partner Gregory Astrachan, of counsel Martin Miller and associates Benjamin Nixon and Bonnie Tice.